Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

MALVERN, Pa. - Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for eye diseases, has received approval from the Data and Safety Monitoring Board (DSMB ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a ...

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.